Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)
Conditions
Brief summary
Although multiple immune-checkpoint inhibitors (ICIs) have demonstrated efficacy in recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M-SCCHN), outcomes in the locally advanced (LA-SCCHN) setting remain suboptimal, and treatment continues to pose a major therapeutic challenge. Incremental improvements in efficacy are still required, necessitating the development of more effective regimens. Whether combining an ICI with chemotherapy and nimotuzumab can confer additional clinical benefit in LA-SCCHN remains to be determined. Against this backdrop, we designed a single-arm, phase II, single-centre clinical trial to evaluate the efficacy and safety of sintilimab plus chemotherapy and nimotuzumab for patients with LA-SCCHN.
Interventions
DRUGSintilimab combined with chemotherapy and nimotuzumab
The study plans to enroll patients with locally advanced squamous cell carcinoma of the head and neck. After induction with sintilimab plus paclitaxel, cisplatin, and nimotuzumab, participants will receive concurrent chemoradiotherapy with nimotuzumab, followed by maintenance sintilimab monotherapy until disease progression, unacceptable toxicity, death, or withdrawal of consent.
Sponsors
Fujian Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Provision of written informed consent, with full understanding of and agreement to comply with study requirements and the visit schedule. 2. Age 18-75 years (inclusive) at the time of informed consent; either sex. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 4. Histologically or cytologically confirmed stage III-IVB squamous cell carcinoma of the head and neck as assessed by the investigator. 5. Documented EGFR-positive tumor. 6. No prior systemic therapy for head and neck squamous cell carcinoma. 7. At least one measurable lesion per RECIST v1.1. 8. Estimated life expectancy ≥ 12 weeks. 9. Adequate bone-marrow and organ function.
Exclusion criteria
1. Known hypersensitivity to any component of PD(L)-1 inhibitors, paclitaxel, or cisplatin. 2. Prior or concurrent malignancy (except adequately treated basal-cell carcinoma, cervical carcinoma in situ, or papillary thyroid carcinoma disease-free for \>5 years). 3. Uncontrolled cardiac symptoms or clinically significant cardiac disease. 4. Previous therapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, or receipt of therapeutic cancer vaccines or live vaccines within 4 weeks before first study-dose administration. 5. Failure to recover to ≤ Grade 1 (per CTCAE) from prior anti-tumour therapy-except alopecia or residual neurotoxicity related to prior platinum-before first study dose. 6. Severe infection (\> CTCAE Grade 2) within 4 weeks before first study dose. 7. Active autoimmune disease or documented autoimmune-disease history requiring systemic therapy. 8. History of immunodeficiency, including positive HIV test, congenital or acquired immunodeficiency syndromes, or prior solid-organ or allogeneic bone-marrow transplantation. 9. History of interstitial lung disease or non-infectious pneumonitis. 10. Evidence of active tuberculosis infection on history or CT imaging. 11. Active hepatitis B (HBV DNA ≥ 500 IU/mL or ≥ 2,500 copies/mL). 12. History of substance abuse, alcohol abuse, or drug addiction. 13. Pregnant or lactating women. 14. Any condition that, in the investigator's opinion, could necessitate premature withdrawal from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Larynx-preservation rate at 3 months post-radiotherapy | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| One-year progression-free survival (PFS) rates | 12 months |
| Two-year progression-free survival (PFS) rates | 24 months |
| One-year loco-regional relapse-free survival (LRFS) rates. | 12 months |
| two-year loco-regional relapse-free survival (LRFS) rates. | 24 months |
| objective response rate | 24 months |
| two-year distant-metastasis-free survival (DMFS) rates | 24 months |
| One-year larynx-preservation rates | 12 months |
| AE/SAE | 42 months |
| One- year distant-metastasis-free survival (DMFS) rates. | 12 months |
Contacts
Primary ContactYun Xu
Outcome results
None listed